Theravance Biopharma
TBPH
118 hedge funds and large institutions have $775M invested in Theravance Biopharma in 2020 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 51 reducing their positions, and 18 closing their positions.
1.35% less ownership
Funds ownership: 83.95% → 82.6% (-1.4%)
6% less funds holding
Funds holding: 125 → 118 (-7)
16% less call options, than puts
Call options by funds: $877K | Put options by funds: $1.04M
29% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 51
30% less capital invested
Capital invested by funds: $1.11B → $775M (-$336M)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$68.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.59M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.62M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$22.4M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$19.6M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
-$10.8M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$7.41M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.72M |
TBPH Hedge Fund Activity: Q3 2020 in Review
118 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2020, worth a combined $775M — down 30% from $1.11B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TBPH and 12 opened new positions — a net loss of 6 holders — while 51 trimmed existing stakes and 36 added.
The largest buyer was OrbiMed, adding an estimated $68.6M. The largest seller was Jane Street, cutting an estimated $22.4M.
- 118 institutional investors held Theravance Biopharma (TBPH) as of Q3 2020, down from 125 in Q2 2020.
- Funds reported $775M of Theravance Biopharma stock for Q3 2020, down 30% quarter-over-quarter.
- 12 funds opened new Theravance Biopharma positions in Q3 2020 and 18 closed out, a net change of -6 holders.
- The largest Theravance Biopharma buyer in Q3 2020 was OrbiMed, an estimated $68.6M added.
- The largest Theravance Biopharma seller in Q3 2020 was Jane Street, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2020.